Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
BioSpace3d
Trump Takes Over, Wegovy Still Trails Zepbound and BioSpace Recaps JPM
Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...
STAT9d
Eli Lilly is considering offering more Zepbound doses in vials at lower cost
When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously ...
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
These stocks have climbed more than 80% and 200% over the past three years. But demand for their products and potential ...
STAT9d
Pharmalittle: We’re reading about lower-priced Zepbound vials, monkey shipments from Cambodia, and more
Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...
Why Novo Nordisk surged 14% on new weight-loss drug results
Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
See ya, knock-off Ozempic
Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
Eli Lilly Shares Fall After GLP-1 Sales Miss Expectations. Is the Stock in Trouble?
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
The Health Risks and Benefits of Weight-Loss Drugs
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
BioWorld1d
Lilly’s Zepbound outpaces Wegovy as December logs 212 trial updates
BioWorld recorded 212 clinical trial updates, an increase from 180 in November and closely aligning with 219 in October. The month saw 16 successful phase III outcomes, along with two mixed results ...